Nanotechnology Now - Press Release: Sigma-Aldrich Streamlines Access to Advanced Stem Cell Research Portfolio and Opens Stem Cell Biology Community Through New Web Portal

Home > Press > Sigma-Aldrich Streamlines Access to Advanced Stem Cell Research Portfolio and Opens Stem Cell Biology Community Through New Web Portal

Abstract:
Regenerative Medicine Team Put in Place to Serve Future Requirements of Stem Cell Researchers

Sigma-Aldrich Streamlines Access to Advanced Stem Cell Research Portfolio and Opens Stem Cell Biology Community Through New Web Portal

ST. LOUIS, MO | Posted on March 11th, 2009

Sigma-Aldrich (Nasdaq: SIAL) today announced the launch of an online web portal that provides researchers with immediate access to its extensive portfolio of industry-leading products developed specifically for advanced stem cell research. The new portal features over 1,100 unique and highly-focused products that are expected to support every step of the stem cell research workflow - from isolation, characterization, expansion, differentiation and functional profiling to in-vitro/in-vivo tracking. In addition, a team of regenerative medicine experts has been retained to continue to identify and develop new and promising technologies in this growing area. The portal also provides access to a robust stem cell biology community and is available at http://www.sigma-aldrich.com/stemcell.

"As a leading destination for life science researchers to access deep biological information and market-leading products, Sigma's focus is to help scientists resolve complex biological questions," said Dr. Dave Smoller, president of the Company's Research Biotech business unit. "Our focus on regenerative medicine and the resulting growing line of stem cell products should help our customers develop cardiac, hematopoietic, endocrine, and neurological disease therapies."

The portal's expanding line of cutting-edge technologies for stem cell research includes the industry's most highly-validated shRNA library, the MISSION(R) RNAi portfolio, which enables gene silencing across a wide range of cellular targets. The site also features the CompoZrTM zinc finger nuclease (ZFN) reagent platform which enables researchers, for the first time, to target and precisely manipulate the genome of both differentiated cells and stem cells, resulting in cell lines or whole organisms with permanent, targeted gene deletions, insertions, or corrections. A complete line of polyclonal and monoclonal antibodies is available, including the Prestige Antibodies(R) collection, considered the industry's most highly characterized line of antibodies. StemlineTM animal serum-free media, essential to many researchers in the expansion and maturation of cell lines, is also available.

Stem cell research has the potential to benefit individuals affected by a wide range of debilitating and life threatening conditions. New approaches are expected to make it possible to reprogram differentiated somatic cells, such as fibroblasts, into stem cells which can then be used for a variety of research applications. Sigma-Aldrich provides access to a growing portfolio of specialized platforms and products to support these businesses.

####

About Sigma-Aldrich
Sigma-Aldrich is a leading Life Science and High Technology company. Its chemical and biochemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 37 countries and has 7,900 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service.

Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Company's expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Company's operations and conditions in the markets the Company serves. The Company does not undertake any obligation to update these forward-looking statements.

Sigma-Aldrich, MISSION, CompoZr, Prestige Antibodies and Stemline are trademarks of Sigma-Aldrich Biotechnology LP and Sigma-Aldrich Co.

For more information, please click here

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: